DK
Therapeutic Areas
Imugene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| azer-cel (azercabtagene zapreleucel) | CD19+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1b |
| onCARlytics (CF33-CD19) | Solid Tumors | Phase 1 |
| VAXINIA (CF33-hNIS) | Advanced Solid Tumors | Phase 1 |
| CHECKvacc | Solid Tumors | Phase 1 |
| HER-Vaxx | HER2+ Gastric/Breast Cancer | Phase 2/3 |
| PD1-Vaxx | Non-Small Cell Lung Cancer (NSCLC) & other solid tumors | Phase 1 |
| CLDN18.2 Program | CLDN18.2+ Gastrointestinal Cancers | Phase 1 |
Leadership Team at Imugene
LC
Leslie Chong
CEO & Managing Director
PH
Paul Hopper
Executive Chairman
UM
Ursula McCurry
Chief Clinical Operations Officer
JB
John Byon
Chief Medical Officer
JD
Jakob Dupont
Non-Executive Director
KD
Kim Drapkin
Non-Executive Director
LR
Lesley Russell
Non-Executive Director
YF
Yuman Fong
Scientific Advisory Board Chair
PS
Prasad S. Adusumilli
Scientific Advisory Board Member
RA
Rebecca Auer
Scientific Advisory Board Member